GSK Acquires Nuvalent for $10.6 Billion to Enter Lung Cancer Precision Targeting Arena

(Source: Economic Information Daily)

Just five months into his tenure, Luke Miels, the new CEO of GlaxoSmithKline (hereinafter referred to as “GSK”), has spearheaded the largest acquisition since he took the helm. Recently, GSK announced its $10.6 billion acquisition of Nuvalent, a U.S.-based clinical-stage biotechnology company, marking a strategic move in the field of precision therapy for lung cancer. This transaction is not only one of the largest acquisitions in GSK’s history but also signals that the century-old pharmaceutical giant is leveraging capital to accelerate efforts to address weaknesses in its oncology portfolio.

Rectifying Strategic Missteps

Under the merger agreement reached by both parties on June 9, GSK will acquire all Class A and Class B common shares of Nuvalent in cash at a price of $124 per share within 10 business days. This price represents a premium of approximately 40% over the closing price on the last trading day prior to the announcement of the transaction. The total equity value of the transaction is £8 billion (approximately $10.6 billion). After deducting approximately $1.2 billion in cash held by Nuvalent, GSK’s net total investment amounts to £7.1 billion (approximately $9.4 billion). The transaction is expected to be completed in the third quarter of 2026, subject to regulatory approvals and the approval of a majority of Nuvalent’s shareholders.

GSK stated that this acquisition aligns with the company’s strategy of acquiring assets with validated targets that effectively address the limitations of existing standard-of-care treatments in terms of efficacy and/or tolerability, and is expected to contribute positively to sales and core operating profit starting from 2027. However, in its 2026 earnings guidance, the company anticipates a low-single-digit decline in earnings per share, taking into account the dilutive impact of the transaction on current-period profits.

From a financial fundamentals perspective, GSK possesses the strength to support this acquisition. In 2025, the company achieved annual revenue of £32.667 billion (approximately $42.794 billion), representing a 7% year-on-year increase; R&D investment amounted to £7.525 billion (approximately $9.858 billion), a 19% year-on-year increase. Notably, the oncology segment performed exceptionally well, with annual revenue reaching £1.977 billion, a significant 43% year-on-year increase. The three major specialty medicine areas—HIV, Respiratory/Immunology, and Oncology—all achieved double-digit growth, with the oncology business becoming GSK’s new growth engine.

From the perspective of industry insiders, GSK’s latest acquisition not only underscores the strategic resolve of its new CEO but also serves as an urgent remedy for a major strategic misstep made a decade ago. In 2015, then-CEO Andrew Witty spearheaded an asset swap deal with Novartis, divesting GSK’s entire oncology business to focus on vaccines, consumer healthcare, and respiratory medicines. The subsequent boom in cancer immunotherapy led this decision to be widely regarded as the biggest strategic blunder in GSK’s history. Marcus Mans, portfolio manager at Union Investment, a GSK shareholder, stated bluntly, “Selling the oncology business in 2015 was absolutely a mistake.” After Emma Walmsley took over as CEO in 2017, GSK began rebuilding its oncology portfolio through mergers and acquisitions, yet it still lags significantly behind oncology giants such as AstraZeneca, Merck, and Roche. In January 2026, upon assuming the role of CEO, Luke Miels clearly positioned the oncology business as one of the group’s core growth engines. This multi-billion-dollar acquisition is a direct manifestation of this strategic transformation.

GSK’s acquisition is not a pursuit of elusive concepts, but rather targets two precision targeted therapies for lung cancer that are nearing market approval, along with a promising early-stage pipeline. Nuvalent’s core assets comprise three lung cancer therapeutics.

Zidesamtinib (NVL-520) is a potential next-generation “best-in-class” ROS1 inhibitor for the treatment of ROS1 fusion-positive non-small cell lung cancer (NSCLC). The drug has been granted Breakthrough Therapy Designation and Orphan Drug Status by the U.S. FDA. Its New Drug Application (NDA) was submitted on a rolling basis starting in September 2025, accepted by the FDA in November of the same year, with a PDUFA (Prescription Drug User Fee Act) target action date of September 18, 2026. Neladalkib (NVL-655) is a potential next-generation “best-in-class” ALK inhibitor for the treatment of ALK-positive NSCLC. This drug has also received Breakthrough Therapy Designation and Orphan Drug Status from the FDA. The NDA was submitted in April 2026, with a PDUFA target action date of November 27, 2026.

From the clinical data perspective, both drugs demonstrate differentiated advantages. In the ALKOVE-1 Phase I/II clinical trial, Neladalkib exhibited durable efficacy in patients who had previously received multiple lines of TKI therapy, achieving an objective response rate (ORR) of 31%, with duration of response (DoR) maintenance rates of 64% and 53% at 12 and 18 months, respectively. Among lorlatinib-naïve patients, the ORR reached as high as 46%; notably, in patients with refractory ALK G1202R mutations, the ORR was 68%. These data support its positioning as a "best-in-class" agent.

The third asset, NVL-330, is a potential “best-in-class” HER2 inhibitor currently being evaluated in the Phase I HEROEX-1 clinical trial in patients with HER2-mutant non-small cell lung cancer (NSCLC), primarily targeting those with HER2 exon 20 insertion mutations and brain metastases, with the aim of avoiding off-target inhibition of wild-type EGFR. Additionally, the transaction includes multiple preclinical programs developed by Nuvalent based on its precision medicine capabilities, further enriching GSK’s early-stage R&D pipeline.

From a portfolio perspective, GSK is not blindly chasing hot targets but aims to build differentiated advantages in the field of lung cancer. The company currently has Ris-Rez, a B7-H3-targeting antibody-drug conjugate (ADC) in Phase III clinical development, along with two precision targeted therapies, Zidesamtinib and Neladalkib, which are expected to form a comprehensive treatment matrix covering the entire disease course from driver gene-positive to refractory non-small cell lung cancer (NSCLC). Luke Mills stated that this acquisition provides a “platform for rapid expansion in the lung cancer space,” creating synergies with its internal pipeline.

Meanwhile, this transaction also bears the significant responsibility of helping GSK address the impending expiration of its core patents and the resulting pressure on declining revenues. The company’s key HIV medication, dolutegravir sodium, will lose its exclusive patent protection in the coming years. Analysts project that if Nuvalent’s two drugs successfully gain regulatory approval and reach the market, they could achieve combined peak sales of $3 billion to $4 billion. This would help mitigate the revenue pressure caused by the patent expirations of GSK’s core products and support the company’s goal of reaching £40 billion in sales by 2031.

Significant Market Divergence

Despite the clear logic behind the deal, market reaction to this sky-high acquisition was not uniformly bullish. On the day the transaction was announced, GSK’s stock price fell by 1.71% to close at $50.64, reflecting to some extent investors’ cautious stance toward the high valuation and competitive pressures.

On one hand, Nuvalent holds approximately $1.2 billion in cash, bringing the net acquisition cost to around $9.4 billion. For a clinical-stage company with only two drugs that have not yet been approved for sale, this valuation signifies that GSK is making a substantial bet on the future market potential of these two drugs. On the other hand, the competitive landscape in the two target areas faced by GSK has become nearly entrenched. In the ROS1 field, Pfizer’s lorlatinib and Roche’s entrectinib already hold first-mover advantages; in the ALK field, Pfizer’s lorlatinib is widely recognized as the “ace.” GSK must demonstrate to physicians and patients that Zidesamtinib and Neladalkib exhibit sufficient efficacy in terms of safety and resistance profiles to support their “best-in-class” positioning.

Barclays analysts deemed the acquisition “sensible,” but cautiously noted that neither of the two drug assets appears to hold “blockbuster” status. Ketan Patel, fund manager at the London family office Whitefriars, also stated that if GSK aims to break into the top tier of the oncology sector, it may need to pursue more high-priced acquisitions in the future.

With the regulatory decision window approaching, the outcome is imminent. For GSK, time is of the essence. The FDA’s approval decisions for zidesamtinib and neladalkib are scheduled for September 18, 2026, and November 27, 2026, respectively. These review outcomes will directly test the worth of GSK’s multi-billion-dollar investment.

Industry insiders point out that if the two drugs are successfully approved and achieve expected market performance, GSK is poised to establish a sustainable competitive advantage in the field of precision therapy for lung cancer, effectively hedging against the pressure from patent expiries of its core products. Conversely, if regulatory approval is hindered or post-launch sales fall short of expectations, this multi-billion-dollar acquisition could drag down the company’s financial performance over the next several years. In any case, the outcome of this major strategic investment will serve as a key barometer for assessing whether GSK can regain its influential voice in the era of precision medicine.